The Systemic Review Of Xuebijing For Treating Immune Dysfunction In Sepsis

ObjectiveTo evaluate the efficacy and safety of xuebijing for immune dysfunction in sepsis.MethodsWe searched the Pubmed, Embase, Cochrane Library, Chinese biological and medical database, VIP Chinese Journals Database, CNKI China National Knowledge Infrastructure Whole Article Database, Wanfang Database by computer up to January 2016. Quasi-randomized controlled trials or randomized controlled trials assessing xuebijing for immune dysfunction in sepsis were selected. Studies were adopted according to the inclusion or exclusion criteria. Two assessors independently extracted data. Reman5.3 was used to undertake meta-analysis.Results8 trials including a total of 502 patients met the inclusion criteria. The results of meta-analysis showed that:1.4 trials reported xuebijing injection for the ratio of HLA-DR, and the meta-analysis showed xuebijing injection could increase the ratio of HLA-DR [MD=8.96,95%CI (2.98,14.94), P=0.003].2.5 trials reported xuebi jing injection on CD4+T lymphocytes, and the meta-analysis showed xuebijing injection could increase levels of CD4+T lymphocytes[MD=3.73,95%CI (3.29,4.17), P<0.00001].3.6 trials reported xuebijing injection on CD8+T lymphocytes, and the meta-analysis showed xuebijing injection could not increase levels of CD8+T lymphocytes[MD=1.33,95%CI (-1.94,4.60), P=0.42].4.6 trials reported xuebijing injection on CD4+/CD8+T lymphocytes ratio, and the meta-analysis showed xuebijing injection could increase levels of CD4+/CD8+T lymphocytes ratio[MD=0.23,95% CI (0.04,0.42), P=0.02].5. Only one trial reported xuebijing injection on 28d mortality with a statistically difference between groups.6.4 trials reported xuebijing injection on APACHE II score, and the meta-analysis showed xuebijing injection could decrease APACHE II score [MD=-2.83,95%CI (-4.82,-0.84), P=0.005].7. All trials did not report adverse events.ConclusionThe available evidence showed that xuebijing injection could improve immune dysfunction in sepsis.Considering the low quality and small sample size,the conclusion should be treated with caution, and more randomized controlled trials with high quality and large sample of xuebijing injection treating immune dysfunction in sepsis are necessary.